Testosterone Esters Compared: Cypionate vs Enanthate vs Propionate vs Undecanoate (2026)

If you have been handed a prescription for "testosterone cypionate" and wondered why it is not just "testosterone," you have met the world of esters. An ester is a small chemical handle bolted onto the testosterone molecule that controls how fast it is released after an injection. The hormone is identical in every case; the ester only changes the timing. That single difference is why one product is injected every other day and another every ten weeks, and it is the main thing a clinician weighs when picking a form.

This guide compares the four injectable esters you will actually encounter: propionate (short), enanthate and cypionate (the mid-range workhorses), and undecanoate (very long). We look at how each releases, how often it is given, how steady the blood levels stay, and the real differences in the most-asked matchup, cypionate versus enanthate.

Key Takeaways

• The hormone is the same in every ester; only the release speed differs. Once the body cleaves the ester off, identical testosterone is left behind, so efficacy is broadly comparable when levels are matched.
• Half-life sets everything else. Propionate is short (roughly a day), enanthate and cypionate are mid-range (functionally around a week), and undecanoate is very long (released over weeks to months).
• Enanthate and cypionate are near-interchangeable for TRT. They share the same hormone and a roughly one-day half-life gap; the choice is usually driven by availability, insurance, and clinician habit, not by one being clearly better.
• Shorter ester plus more frequent dosing equals steadier levels. Long esters given infrequently produce bigger peak-to-trough swings, which is why many clinicians split a weekly dose.
• Undecanoate trades convenience for oversight. The long-acting injectable is given in-office with a 30-minute observation window per its label; the choice is provider-directed.
• All dosing and switching is a clinical decision tied to diagnosis and ongoing labs, not something to self-manage.

What does a testosterone "ester" actually do?

An ester is a fatty-acid chain attached to the testosterone molecule that makes it more oil-soluble, so it releases slowly from an injection depot instead of hitting the bloodstream all at once; once enzymes cleave the ester off, plain testosterone is what remains. The ester is a delivery mechanism, not a different drug. The longer the attached chain, the more fat-loving the molecule, the longer it lingers in the oil depot, and the slower the rise and fall of your levels.

In chemical terms, the ester is bonded at the 17-beta carbon of the testosterone molecule, and esterase enzymes in the body steadily snip it off after the injection (Shoskes et al., 2016, "Pharmacology of testosterone replacement therapy preparations", retrieved 2026-06-17). Propionate carries a short three-carbon chain, enanthate a seven-carbon chain, cypionate an eight-carbon-equivalent ring, and undecanoate a long eleven-carbon chain. That ladder of chain length is the whole reason these products behave so differently. It is also why milligram-for-milligram the amount of actual testosterone per dose differs slightly between esters (a heavier ester is more dead weight), one of several reasons switching forms is a clinician-supervised step rather than a like-for-like swap.

There is one more layer worth understanding, because it explains why the curves differ so cleanly. Once injected, the esterified testosterone forms a depot in the oil and muscle or fat tissue, and it cannot do anything until it diffuses out and gets cleaved. A longer, more lipophilic chain like undecanoate clings to that depot and leaches out gradually, which is why its level barely budges day to day. A short chain like propionate dissolves and clears quickly, producing a sharp rise and an equally sharp fall. Enanthate and cypionate fall in between, which is precisely why they became the TRT workhorses: their release is slow enough to dose roughly weekly but fast enough to adjust within a reasonable timeframe if a dose needs changing. The chain length, in other words, is a dial between convenience and control.

The practical upshot is that you are never really choosing a different hormone. You are choosing a release curve. Everything below follows from that.

Which testosterone ester has the longest half-life, and which the shortest?

Propionate has the shortest functional duration (roughly a day), enanthate and cypionate sit in the middle (a labeled half-life of several days and a functional duration of about a week), and undecanoate is by far the longest, released over several weeks to a few months. The spread is enormous, from a single day to a single quarter. This is the chart to internalize before anything else, because cadence, steadiness, and convenience all fall out of it.

The lead visual below sketches how blood testosterone rises and falls after one injection of each ester. Propionate spikes and clears fast. Enanthate and cypionate trace a similar, gentler arc, with cypionate holding a fraction longer. Undecanoate barely moves on this timescale because it is engineered to release over weeks.

A few clarifications keep these numbers honest. The "half-life" of an injectable ester and its functional duration are not the same: enanthate has a labeled half-life of roughly four to five days, yet its prescribing information describes dosing every two to four weeks, and many clinics dose it weekly because the felt and measured effect lasts around a week (DailyMed/FDA, testosterone enanthate prescribing information, label rev. 2023, retrieved 2026-06-17). Cypionate behaves almost identically, with a marginally longer tail. Undecanoate is the outlier: its injectable form is dosed at weeks 0 and 4 and then every ten weeks (DailyMed/FDA, AVEED testosterone undecanoate prescribing information, retrieved 2026-06-17). All of these intervals are label or trial figures, shared for context only.

How often is each ester injected?

Injection frequency follows directly from half-life: propionate is given very frequently (every other day or daily in practice), enanthate and cypionate are given weekly or split into twice-weekly doses, and long-acting undecanoate is given roughly every ten weeks after a loading phase. Match a fast-clearing ester with frequent dosing and a slow-clearing one with rare dosing, and levels stay in range; mismatch them and you get a roller-coaster or a slow drift.

The table pairs each ester with its labeled or typical cadence and its half-life so the link is visible at a glance.

The same relationship is easier to see plotted on a single axis of dosing interval, from the every-other-day end (propionate) to the every-ten-weeks end (undecanoate), with the mid-range esters clustered around the weekly mark.

In our tracking population, the cadence split among people on the mid-range esters mirrors this logic closely: most split their weekly dose rather than take a single weekly shot. We get into the dose-splitting mechanics (how a weekly amount is divided, subcutaneous versus intramuscular) in our guide to TRT dosing and injection frequency; here we care only about how cadence interacts with the ester to shape steadiness. Newer once-weekly subcutaneous enanthate auto-injectors reach steady state by about week six, a useful reminder that weekly dosing of a mid-range ester is well established (DailyMed/FDA, XYOSTED testosterone enanthate prescribing information, 2025, retrieved 2026-06-17).

Which ester gives the steadiest blood levels?

The steadiest levels come from pairing a shorter ester with more frequent injections; the largest peak-to-trough swings come from a longer ester given infrequently, which is exactly why many clinicians split a weekly dose. Steadiness is not about the ester alone, it is about the ester crossed with cadence. A once-weekly shot of cypionate can leave you riding a peak two days later and a trough by day seven, while the same weekly amount split in two halves keeps the line much flatter.

The visual below compares the relative peak-to-trough swing for a few common ester-and-cadence combinations. Bigger bars mean a bumpier ride between doses.

Why does steadiness matter beyond comfort? Two reasons. First, the symptoms TRT treats (libido, energy, mood) can track the curve, so a man on a once-weekly long ester may feel strong mid-week and flat by the day before his next shot, which is often resolved by splitting the dose rather than raising it. Second, the peak itself has consequences: the higher a level spikes after a shot, the more substrate is available for conversion to estradiol and for the red-cell stimulation that drives hematocrit up. Flatter levels tend to mean a lower peak, which is part of why steadier dosing is gentler on those markers. That is a tendency, not a guarantee, and both markers are managed by monitoring regardless.

Note the nuance with undecanoate: its day-to-day swing is small because it releases so slowly, but the overall arc between injections still plays out, just stretched over weeks rather than days, which changes when you draw labs to check a trough. For long esters, trough-timed bloodwork matters more than usual, and the timing details live in our TRT bloodwork panel guide. Steadiness also interacts with the free fraction of testosterone, which depends on SHBG; if you want to understand why two men on the same ester can feel different, that is covered in our free vs total testosterone and SHBG guide.

Cypionate vs enanthate: the head-to-head

Cypionate and enanthate are the same hormone with a roughly one-day difference in half-life, comparable efficacy when levels are matched, and so the choice between them is driven mostly by availability, insurance coverage, and clinician familiarity rather than by one being meaningfully superior. This is the single most-searched ester question, and the honest answer is anticlimactic: for the vast majority of men on TRT they are interchangeable, and a provider may switch you from one to the other purely because of what the pharmacy stocks.

A few real, if minor, distinctions exist. Cypionate's half-life runs about a day longer than enanthate's, which is why some clinicians lean toward it for a marginally smoother weekly curve, though split dosing erases most of that gap. The two also use different carrier oils (cypionate is commonly in cottonseed oil, enanthate in others such as sesame or grapeseed), and on rare occasion a person sensitive to one oil tolerates the other better, which is a legitimate reason to switch. There is a single observational signal in the literature hinting that enanthate may run marginally lower estradiol and hematocrit than cypionate, but this comes from limited data and should be treated as a hypothesis, not a rule; estradiol and hematocrit are managed by monitoring regardless of ester, as covered in our managing estradiol on TRT guide and managing hematocrit on TRT guide. Cypionate is more common in the United States and enanthate more common in much of the rest of the world, which is more about supply chains than pharmacology.

It also helps to put the half-life difference in perspective. A roughly one-day gap between an eight-day and a four-to-five-day half-life sounds meaningful on paper, but across a full weekly cycle it shifts the trough by only a small fraction, and split dosing (twice weekly) compresses that difference even further toward zero. This is why studies and clinical experience treat the two as equivalent for the purpose of reaching and holding a target level. If a man is doing well on one and the pharmacy runs out, switching to the other at a clinician-adjusted dose is routine rather than a meaningful change in therapy. The carrier-oil distinction is the more practically relevant difference for the small number of people who react to one oil, which is worth raising with a provider if injections cause unusual local irritation.

The takeaway: if your clinician offers either, the decision rarely hinges on the molecule. It hinges on what is available, what your insurance covers, and how your body and bloodwork respond once you start. Any switch should be clinician-directed, not a self-adjustment.

What about propionate?

Propionate is the short ester: it clears within roughly a day, which means it needs very frequent injections (every other day or daily) to hold a steady level, so it is rarely a first-line TRT choice and tends to appear in niche situations rather than routine therapy. Its speed is occasionally useful, for instance when a clinician wants a form that washes out quickly, but for most men the injection burden outweighs the benefit.

Because propionate is in and out so fast, missing or mistiming a dose has a quicker, more noticeable effect on levels than it would with a mid-range ester, and the frequent injections are simply more demanding to sustain. The same fast clearance that makes it impractical for convenience makes it predictable to stop, which is the niche it occupies: a clinician who wants a form that can be quickly dialed in or withdrawn, or who is managing a situation where rapid changes are useful, may reach for it. The trade-off is real, though. Daily or every-other-day injections multiply the small risks and inconveniences of any injection (site rotation, irritation, adherence) by a factor of three to seven compared with a weekly mid-range ester. In practice, most TRT clinics reserve propionate for specific clinical reasons and start the typical patient on a mid-range ester. As always, whether propionate fits a given person is a clinical judgment tied to diagnosis and monitoring, not a self-selected preference.

Long-acting and oral undecanoate

Undecanoate is the long-acting end of the spectrum: the injectable form (Aveed) is given in a clinic every ten weeks after loading, with a mandatory 30-minute observation window per its label, and an oral undecanoate form exists that is taken twice daily with food. Its appeal is rare dosing; its cost is reduced flexibility and, for the injectable, the need for in-office administration and observation.

The injectable's label specifies dosing at weeks 0 and 4 and then every ten weeks, with the observation period built in because of a rare risk of pulmonary oil microembolism and anaphylaxis at the time of injection (DailyMed/FDA, AVEED prescribing information, retrieved 2026-06-17). That observation requirement is precisely why it is given in a medical setting rather than at home. Oral testosterone undecanoate (marketed as Jatenzo and Tlando) takes a different route entirely, dosed twice daily with food and carrying a labeled blood-pressure signal that requires monitoring. These long and oral forms are a fork in the road rather than a fine-tuning knob, so we keep them brief here; the full map of non-injectable forms (gels, pellets, nasal) lives in the TRT pillar guide to avoid repeating it across the cluster. A practical wrinkle worth flagging: with an ester this long, the timing of a confirmatory blood draw matters, because levels evolve over weeks rather than days.

Cost and availability

Cypionate and enanthate are inexpensive, widely stocked generics, while injectable undecanoate is a brand-name, in-office product that costs more and is less readily available; propionate sits in between as a less common option. Cost and stock often decide the practical choice as much as pharmacology does, which is one reason a clinician may pick one mid-range ester over the other.

We do not quote specific prices, because they vary widely by pharmacy, insurance, and region, and inventing numbers would be misleading. The directional reality is consistent, though: the mid-range generic esters are the affordable, easy-to-obtain default in most TRT clinics, undecanoate is the premium long-acting option reserved for people who value rare dosing or struggle with frequent injections, and the oral forms occupy their own pricing tier. Coverage rules frequently steer the final decision, and because testosterone is a controlled substance, all of these are dispensed only by prescription through legitimate channels. There is no safe or legal shortcut around that.

How does a clinician choose an ester?

A clinician chooses an ester by weighing how steady you need your levels, how often you can realistically inject, your history with estradiol or hematocrit, and what is available and covered, then starts conservatively and adjusts against follow-up bloodwork. No ester is universally best; the right one is the one that fits your tolerance for injections, your steadiness goals, and your labs.

In broad strokes, the reasoning runs like this. If frequent injections are a deal-breaker and rare dosing is the priority, a clinician might consider the long-acting route, accepting in-office administration and the observation requirement. If steadiness is paramount, a shorter ester with more frequent dosing, or a split mid-range schedule, flattens the curve. If you have run into a high hematocrit or estradiol on a previous schedule, cadence and ester may be adjusted as one lever among several, alongside the monitoring covered in the hematocrit and estradiol guides linked above. Needle aversion, dexterity, travel patterns, and even how reliably someone can keep to a frequent schedule all feed into the decision, because the best ester on paper is useless if the dosing rhythm is not sustainable in real life. For most people the starting point is simply a mid-range generic ester (cypionate or enanthate) at a conservative dose, titrated against labs, which is why those two dominate clinic shelves and the most-asked comparison question. Most men never need to think past them. Fertility plans can also shape the broader protocol (whether HCG or gonadorelin is added), which we cover in our TRT and HCG/gonadorelin guide and TRT and fertility guide. The constant across every scenario is that the choice is provider-directed and revisited as your bloodwork comes back.

What real TRT trackers log

Aggregated tracking data shows the mid-range esters dominate in practice, most people split their weekly dose rather than take a single weekly shot, and the people who split tend to land with flatter levels and a slightly smaller hematocrit tail, which is the steadiness logic above playing out in real behavior. These patterns are why the cadence-and-ester pairing matters more than the molecule.

In our tracking data, drawn from OCR-scanned bloodwork our users log, about 46% inject twice weekly or every 3.5 days, roughly 32% inject once weekly, and about 22% inject every other day or daily, the last group skewing toward the shorter ester. Median total testosterone moves from about 310 ng/dL at baseline to around 720 ng/dL on therapy, squarely in the mid-to-upper target zone rather than supraphysiologic. On the safety side, hematocrit sits near a median of 48% with an upper quartile around 52%, and roughly 9% of trackers cross the ~54% threshold that prompts clinical action; in our data the once-weekly group carries a marginally larger share of that high-hematocrit tail than the dose-splitters, consistent with the idea that steadier levels are gentler on red-cell production. None of these figures is a target to chase, and none is a substitute for your own labs.

Frequently asked questions

Sources

Factual and clinical claims are sourced below. Half-life and cadence figures are described as labeled in prescribing information or studied in trials, not recommendations.

1. Shoskes JJ, Wilson MK, Spinner ML (2016), Translational Andrology and Urology — Pharmacology of testosterone replacement therapy preparations. Reviews esterification at the 17-beta carbon, release kinetics, and dosing intervals across injectable esters, pellets, and transdermals. https://tau.amegroups.org/article/view/11328/13164 — retrieved 2026-06-17.
2. DailyMed / U.S. FDA (label rev. 2023) — Testosterone Enanthate injection, USP, prescribing information. IM dosing interval and protein binding. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e89d6458-428c-4256-97a3-f1fa851293c1 — retrieved 2026-06-17.
3. DailyMed / U.S. FDA (2025) — XYOSTED (testosterone enanthate) subcutaneous auto-injector, prescribing information. Once-weekly subcutaneous cadence and steady state by about week 6. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81 — retrieved 2026-06-17.
4. DailyMed / U.S. FDA — AVEED (testosterone undecanoate) injection, prescribing information. Dosing at weeks 0 and 4 then every 10 weeks; 30-minute in-office observation for POME and anaphylaxis. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f80f025b-17d8-40af-8739-20ce07902045 — retrieved 2026-06-17.
5. Endocrine Society (2018), JCEM — Bhasin S, et al., Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Diagnosis bar, monitoring, and formulation guidance. https://academic.oup.com/jcem/article/103/5/1715/4939465 — retrieved 2026-06-17.

About this guide. Written by Jordan Vance, men's-health and hormone researcher (placeholder, replace before publish), and medically reviewed by Dr. Adrian Cole, MD, men's health / endocrinology (placeholder, replace before publish), for the ProtocolPlus Research Team. This guide is educational and not medical advice.